AI integration moves from experimentation to enterprise-wide deployment. Clinical readouts reinforce the difficulty of beating established immunotherapy standards, while positive data in infection, rare disease & metabolic disease highlight ongoing unmet need. A meaningful regulatory approval addresses treatment-resistant hypertension. Biosimilar launches continue to erode branded franchises. Across the week, the gap between scientific promise and commercial reality remains a

This week's edition of Pharma Phriday (April 10, 2026) spans late-stage clinical results in thyroid eye disease, achondroplasia, small cell lung cancer, hidradenitis suppurativa, macular degeneration, and inflammatory respiratory conditions; regulatory approvals and submissions in rare and chronic disease; and a flurry of M&A and partnership activity spanning oncology, rare disease, and drug delivery innovation.